Commerzbank Analysts Give Fresenius SE & Co KGaA (FRE) a €83.00 Price Target

Commerzbank set a €83.00 ($96.51) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research note published on Wednesday morning. The firm currently has a buy rating on the stock.

FRE has been the topic of a number of other reports. Berenberg Bank set a €81.85 ($95.17) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Tuesday, July 31st. UBS Group set a €59.00 ($68.60) price target on Fresenius SE & Co KGaA and gave the company a sell rating in a research note on Tuesday, June 26th. Goldman Sachs Group set a €72.00 ($83.72) price target on Fresenius SE & Co KGaA and gave the company a neutral rating in a research note on Tuesday, July 31st. Sanford C. Bernstein set a €83.00 ($96.51) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Tuesday, July 3rd. Finally, Independent Research set a €80.00 ($93.02) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Tuesday, July 31st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company’s stock. Fresenius SE & Co KGaA currently has a consensus rating of Buy and a consensus price target of €76.44 ($88.89).

Shares of FRA FRE opened at €59.84 ($69.58) on Wednesday. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: Trading Strategy Methods for Individual Investors

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply